Protein-tyrosine phosphatases and cancer.
Tyrosine phosphorylation is an important signalling mechanism in eukaryotic cells. In cancer, oncogenic activation of tyrosine kinases is a common feature, and novel anticancer drugs have been introduced that target these enzymes. Tyrosine phosphorylation is also controlled by protein-tyrosine phosphatases (PTPs). Recent evidence has shown that PTPs can function as tumour suppressors. In addition, some PTPs, including SHP2, positively regulate the signalling of growth-factor receptors, and can be oncogenic. An improved understanding of how these enzymes function and how they are regulated might aid the development of new anticancer agents.
Cancer Center Karolinska, Department of Pathology and Oncology, Karolinska Institutet, Stockholm, Sweden.
Arne
A
Ostman
Carina
C
Hellberg
Frank D
FD
Böhmer
D000818:Animals; D066246:ErbB Receptors / Q000378:metabolism; D006801:Humans; D009369:Neoplasms / Q000201:enzymology* / Q000628:therapy; D010766:Phosphorylation; D017027:Protein Tyrosine Phosphatases / Q000235:genetics / Q000378:metabolism*; D014443:Tyrosine
D014443:Tyrosine; D066246:ErbB Receptors; D017027:Protein Tyrosine Phosphatases